It turns out that publication bias was rampant. Pfizer and Lundbeck, the two companies running the studies, didn’t publish a lot of their data, especially the data showing no effect and unfortunate side effects

via Guest Blog: The antidepressant reboxetine: A headdesk moment in science.

If something as simple as selectively reporting results gets drugs past FDA screening, something is horribly broken in pharmacology. I know the patent cliff is putting a lot of pressure on the larger pharma companies, but this kind of outright lying by omission is surely not legal.